Publications by authors named "Maluki Radford"
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients ≥80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy.
View Article and Find Full Text PDFArticle Synopsis
- - Geriatric patients aged 80 and older are often excluded from clinical trials for immune checkpoint inhibitors (ICIs), despite their potential different responses due to unique biological factors.
- - A study analyzed data from 885 patients treated with ICIs, finding that those aged 80 and above with low levels of inflammatory markers (NLR and SII) exhibited significantly better treatment responses and longer survival outcomes.
- - The research suggests that lower inflammatory levels before starting ICI treatment can be a useful predictor for improved effectiveness and survival rates in older cancer patients.
-targeted therapy with the monoclonal antibody trastuzumab has achieved impressive outcomes in the first-line settings of patients with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing . However, considering that a substantial proportion of those patients eventually relapses, as well as the relatively limited performance of those agents in second-line settings, a deeper understanding of resistance mechanisms is needed for enhanced guidance for patients' therapeutic selection in the second-line setting and beyond. In this review, we highlight trastuzumab's (-targeting agent) performance in patients with gastric or GEJ cancer, with insight into mechanisms of resistance.
View Article and Find Full Text PDFImportance: Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population.
View Article and Find Full Text PDFArticle Synopsis
- Microsatellite instability-high/deficient mismatch repair colorectal cancer (MSI-H/dMMR CRC) is a subtype of cancer that has a high rate of mutations due to faulty DNA mismatch repair, leading to the creation of neoantigens that can be targeted by treatments.
- Immune checkpoint inhibitors (ICIs) have been particularly effective in treating this type of cancer, resulting in significant clinical benefits, as highlighted by major clinical trials leading to FDA approvals.
- The article reviews the molecular reasons for how these tumors respond to ICIs, discusses resistance mechanisms, and presents ongoing research aimed at improving immunotherapy strategies for better long-term outcomes.